Filing Details

Accession Number:
0000921895-23-002475
Form Type:
4
Zero Holdings:
No
Publication Time:
2023-11-06 18:07:28
Reporting Period:
2023-11-02
Accepted Time:
2023-11-06 18:07:28
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1815442 Kymera Therapeutics Inc. KYMR Investment Advice (6282) DE
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
918923 P L Fund Value Biotechnology 44 Montgomery Street
40Th Floor
San Francisco CA 94104
Yes No No Yes
1055947 P/Il L Partners Bvf 44 Montgomery Street
40Th Floor
San Francisco CA 94104
Yes No No Yes
1056807 Bvf Inc/Il 44 Montgomery Street
40Th Floor
San Francisco CA 94104
Yes No No Yes
1102444 Biotechnology Value Fund Ii Lp 44 Montgomery Street
40Th Floor
San Francisco CA 94104
Yes No No Yes
1233840 N Mark Lampert 44 Montgomery Street
40Th Floor
San Francisco CA 94104
Yes No No Yes
1660683 Biotechnology Value Trading Fund Os Lp P.o. Box 309 Ugland House
Grand Cayman E9 KY1-1104
Yes No No Yes
1660684 Ltd. Os Partners Bvf P.o. Box 309 Ugland House
Grand Cayman E9 KY1-1104
Yes No No Yes
1803805 Bvf I Gp Llc 44 Montgomery Street
40Th Floor
San Francisco CA 94104
Yes No No Yes
1803806 Bvf Ii Gp Llc 44 Montgomery Street
40Th Floor
San Francisco CA 94104
Yes No No Yes
1803809 Bvf Gp Holdings Llc 44 Montgomery Street
40Th Floor
San Francisco CA 94104
Yes No No Yes
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, $0.0001 Par Value Acquisiton 2023-11-02 57,618 $11.64 2,552,306 No 4 P Direct
Common Stock, $0.0001 Par Value Acquisiton 2023-11-02 132,016 $11.64 2,020,367 No 4 P Direct
Common Stock, $0.0001 Par Value Acquisiton 2023-11-02 26,772 $11.64 284,526 No 4 P Direct
Common Stock, $0.0001 Par Value Acquisiton 2023-11-03 103,885 $14.07 2,656,191 No 4 P Direct
Common Stock, $0.0001 Par Value Acquisiton 2023-11-03 83,708 $14.07 2,104,075 No 4 P Direct
Common Stock, $0.0001 Par Value Acquisiton 2023-11-03 10,106 $14.07 294,632 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
No 4 P Direct
No 4 P Direct
No 4 P Direct
No 4 P Direct
No 4 P Direct
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Common Stock, $0.0001 Par Value Stock Option (Right to Buy) $27.67 2033-06-14 12,000 12,000 Indirect
Common Stock, $0.0001 Par Value Stock Option (Right to Buy) $20.00 2030-08-19 40,127 40,127 Indirect
Common Stock, $0.0001 Par Value Stock Option (Right to Buy) $49.10 2031-06-15 20,063 20,063 Indirect
Common Stock, $0.0001 Par Value Stock Option (Right to Buy) $14.18 2032-06-14 12,000 12,000 Indirect
Expiration Date Amount Remaning Holdings Nature of Ownership
2033-06-14 12,000 12,000 Indirect
2030-08-19 40,127 40,127 Indirect
2031-06-15 20,063 20,063 Indirect
2032-06-14 12,000 12,000 Indirect
Footnotes
  1. This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
  2. Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.
  3. Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.
  4. Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.
  5. Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Mr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Mr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
  6. The shares underlying this stock option shall vest in full upon the earlier to occur of (i) June 15, 2024 and (ii) the date of the next annual meeting of the Issuer's stockholders.
  7. The shares subject to the option have fully vested.
  8. The shares subject to the option have fully vested.
  9. The shares subject to the option have fully vested.